The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
- 31 March 1993
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 44 (4-6) , 687-691
- https://doi.org/10.1016/0960-0760(93)90283-3
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase InhibitorJournal of Clinical Endocrinology & Metabolism, 1991
- Endocrine Treatment of Breast Cancer in WomenEndocrine Reviews, 1990
- A phase I trial of CGS 16949a. A new aromatase inhibitorCancer, 1990
- Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*Journal of Clinical Endocrinology & Metabolism, 1989
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978
- Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancerCancer, 1974